Abraxis adds 50,750-square-foot facility, lays groundwork for biopharmaceutical campus

By Lisa Kerner

Erie, Pa., May 18 - Abraxis BioScience, Inc. increased the size of its research facilities with the addition of a 50,750-square-foot facility, featuring 20,000 square feet of cGMP-compliant product space, located in Marina del Rey, Calif.

The facility, formerly owned by CancerVax, Inc., is designed for the manufacture of clinical trial materials for cell-based biotechnology products including whole cell vaccines and stem cell therapies, according to a company news release.

Abraxis said it will use the facility to expand its research and process development capabilities, including biosimilars, as well as house the company's regulatory affairs and medical writing staff.

The facility will also support ongoing development of therapeutic agents using Abraxis' proprietary nab technology platform.

Abraxis purchased an additional 3.5-acre property in Culver City, Calif., as a foundation for its biopharmaceutical campus in Los Angeles scheduled for completion in 2008.

Based in Los Angeles, Abraxis develops, manufactures and markets injectable products and therapeutics for the treatment of cancer and other life-threatening diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.